Arbovirus Infections: Clinical Trials

390 completed, 66 unknown, 45 recruiting, 27 active not recruiting. 129 Phase 2, 124 Phase 1, 97 Phase 3, 75 Not applicable, 38 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	129	Completed 86, Unknown 13, Recruiting 12, Active not recruiting 6, Terminated 6, Withdrawn 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 1	124	Completed 105, Terminated 4, Unknown 4, Withdrawn 4, Not yet recruiting 3, Recruiting 3, Active not recruiting 1
Phase 3	97	Completed 67, Recruiting 9, Unknown 8, Active not recruiting 5, Not yet recruiting 3, Terminated 3, Withdrawn 2
Not applicable	75	Completed 41, Unknown 9, Terminated 8, Not yet recruiting 6, Recruiting 6, Active not recruiting 3, Enrolling by invitation 1, Suspended 1
Phase 4	38	Completed 31, Unknown 5, Active not recruiting 1, Recruiting 1
Early Phase 1	6	Completed 2, Not yet recruiting 2, Unknown 2

Follow Arbovirus Infections: new trials by email Literature Review of Arbovirus Infections trials Research Report on Arbovirus Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal	Not applicable	Recruiting	Centre Hospitalier Universitaire de la Réunion	60	2027-08-01	2026-09-15
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya	Phase 3	Not yet recruiting	Butantan Institute	900	2027-03-31	2026-07-16
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind	Phase 1	Not yet recruiting	VLP Therapeutics	42	2027-01-04	2026-09-21
Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue		Not yet recruiting	Liverpool School of Tropical Medicine	235	2026-11-01	2026-09-02
Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue	Phase 3	Not yet recruiting	Oxford University Clinical Research Unit, Vietnam	8800	2026-10-01	2026-04-21
Evaluation of IXCHIQ® Vaccine Immunogenicity IXCHIQ vaccine - Healthy Adult, Healthy Adolescents	Phase 2	Not yet recruiting	Mauro Martins Teixeira	75	2026-09-24	2026-09-29
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue	Phase 2 / Phase 3	Recruiting	Johns Hopkins University	600	2026-09-01	2026-10-13
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants Skin punch biopsy, Blood samples - Yellow Fever (Healthy Volunteers), Biopsy/Methods	Not applicable	Recruiting	Institute of Tropical Medicine, Belgium	40	2026-08-10	2026-08-13
Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19	Not applicable	Enrolling by invitation	Peking University	108	2026-08-10	2026-08-19
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	200	2026-08-07	2026-10-22
A Phase I Study of PepGNP-ChikV in Healthy Volunteers PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever	Early Phase 1	Not yet recruiting	Gylden Pharma Ltd	40	2026-08-03	2026-04-29
Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever		Recruiting	University of Oxford	190	2026-08-01	2026-08-06
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya	Not applicable	Not yet recruiting	Universidade do Estado do Pará	54	2026-07-01	2026-05-26
VLA1553-403 Pregnancy Surveillance Study Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH - Chikungunya Virus Infection		Enrolling by invitation	Valneva Austria GmbH	200	2026-06-11	2026-07-20
UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF Favipiravir, Ribavin, Optimised Standard of Care - Crimean-Congo Hemorrhagic Fever	Phase 2	Recruiting	Liverpool School of Tropical Medicine	378	2026-06-04	2026-08-07
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus	Phase 3	Recruiting	Bavarian Nordic	6144	2026-05-26	2026-06-29
Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care Rapid Diagnostic Test - Crimean-Congo Haemorrhagic Fever	Not applicable	Recruiting	Liverpool School of Tropical Medicine	492	2026-05-04	2026-06-09
Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs	Phase 2	Recruiting	Oxford University Clinical Research Unit, Vietnam	500	2026-04-20	2026-09-28
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection	Phase 2 / Phase 3	Recruiting	Bharat Biotech International Limited	1000	2026-04-20	2026-04-29
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue	Phase 2 / Phase 3	Recruiting	Hyundai Bioscience Co., Ltd.	210	2026-04-09	2026-07-10

Showing 20 of 593. Sign in to see all of them.

Narrower conditions

Dengue (275)  ·  Chikungunya Fever (88)  ·  Zika Virus Infection (77)  ·  Encephalitis, Japanese (72)  ·  Severe Dengue (65)  ·  Encephalitis, Tick-Borne (50)  ·  Yellow Fever (44)  ·  Virus Diseases (23)  ·  Encephalitis (15)  ·  Flavivirus Infections (12)  ·  Malaria (12)  ·  West Nile Fever (12)  ·  Hemorrhagic Fevers, Viral (11)  ·  Rift Valley Fever (11)

Broader conditions

Infections (590)  ·  Vector Borne Diseases (587)  ·  RNA Virus Infections (582)  ·  Virus Diseases (570)  ·  Mosquito-Borne Diseases (529)  ·  Flaviviridae Infections (499)  ·  Flavivirus Infections (489)  ·  Hemorrhagic Fevers, Viral (327)  ·  Nervous System Diseases (156)  ·  Central Nervous System Diseases (148)  ·  Neuroinflammatory Diseases (148)  ·  Central Nervous System Infections (147)  ·  Brain Diseases (146)  ·  Encephalitis, Arbovirus (146)

Interventions

Vaccines (23)  ·  Yellow Fever Vaccine (18)  ·  Blood Specimen Collection (17)  ·  Dengue Vaccines (14)  ·  Sodium Chloride (14)  ·  Japanese Encephalitis Vaccines (11)  ·  Measles-Mumps-Rubella Vaccine (7)  ·  Aluminum Hydroxide (5)  ·  Data Collection (5)  ·  Saline Solution (5)  ·  Surveys and Questionnaires (5)  ·  Desiccation (4)  ·  Hepatitis A Vaccines (4)  ·  Ribavirin (4)  ·  Urination (4)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (58)  ·  Sanofi Pasteur, a Sanofi Company (49)  ·  Valneva Austria GmbH (28)  ·  U.S. Army Medical Research and Development Command (26)  ·  Pfizer (19)  ·  Takeda (18)  ·  Sanofi (15)  ·  Bavarian Nordic (9)  ·  Centre Hospitalier Universitaire de la Réunion (9)  ·  University of Oxford (9)  ·  Mahidol University (8)  ·  Institut Pasteur (7)  ·  Institute of Tropical Medicine, Belgium (7)  ·  PATH (7)  ·  University Medical Centre Ljubljana (7)

Countries

United States (149)  ·  Brazil (51)  ·  Thailand (43)  ·  Colombia (30)  ·  France (25)  ·  Germany (24)  ·  Mexico (24)  ·  Puerto Rico (24)  ·  Philippines (22)  ·  Austria (21)  ·  Singapore (21)  ·  Vietnam (21)  ·  Malaysia (20)  ·  China (14)  ·  Australia (12)

Top investigators

Anna Durbin, MD (30)  ·  Beth Kirkpatrick, MD (4)  ·  Kristen Pierce, MD (4)  ·  Astrid Kaltenboeck, Ph.D. (3)  ·  Clemente Diaz, MD (3)  ·  Myrielle Dupont-Rouzeyrol, PhD (3)

Results publications

PMID 40099800, PMID 42253092, PMID 26214039, PMID 29897841, PMID 33822015, PMID 26383952, PMID 29217375, PMID 31878895, PMID 35709798, PMID 39116904, PMID 20934459, PMID 21592984, PMID 23563266, PMID 25801652, PMID 26424605, PMID 26458804, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28545923, PMID 28871961, PMID 29300876, PMID 31984244, PMID 32220283, PMID 32394880, PMID 32497524, PMID 32572470, PMID 32932330, PMID 33212068, PMID 33422034, PMID 34003796, PMID 34107180, PMID 34219653, PMID 35659904, PMID 36057771, PMID 36682364, PMID 37254133, PMID 37321235, PMID 37971871, PMID 38294972, PMID 39308445, PMID 39356094, PMID 42480195, PMID 10632996, PMID 15272410, PMID 15499438, PMID 15577938, PMID 15714427, PMID 15741556, PMID 16269927

NIH funding

2014 (7), 2019 (4), 2018 (3), 2009 (2), 2023 (2), U19AI057266 (2), 2008 (1), 2015 (1), 2016 (1), 2025 (1), 272201300017C-18-0-1 (1), R01HD102445 (1), R21AI139777 (1), R21HD095420 (1), R21HD096369 (1)